Imprimis Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

MKO (midazolam, ketamine, and ondansetron)

Imprimis Pharmaceuticals has secured a patent covering the company's MKO (midazolam, ketamine, and ondansetron) Melt compounded formulation from the US Patent and Trademark office. US Patent 9,918,993 B2 entitled "Pharmaceutical compositions for anesthesiological applications" was issued on March 20, 2018.

"We are pleased to have been granted this patent which covers our MKO Melt formulation and a variety of other versions of midazolam and ketamine combinations we intend to make available to address unmet patient needs,” Mark L. Baum, CEO of Imprimis, said. “Since we first made the MKO Melt available in 2015, it has been dispensed as a compounded formulation over 70,000 times, used primarily prior to and during cataract surgery." John Berdahl, MD, board-certified ophthalmologist and inventor of the MKO Melt, added, "We have completed more than 10,000 cataract surgeries using the MKO Melt and have had great success with it. We have found that it offers unique benefits to patients who may not be well suited for traditional IV sedation. I am pleased it is now protected by this newly issued patent, and potentially, other procedural sedation patent applications that remain pending."

  • <<
  • >>

Comments